source
- Lonza plans new ADC manufacturing site and workforce boost to capture commercial marketLonza said it aims to become a leading supplier of antibody-drug conjugates (ADCs) for commercial use. The Swiss contract manufacturing organization highlighted the growing demand for ADCs and its…
- FDA accepts supplemental NDA for taletrectinib targeting ROS1‑positive lung cancerThe U.S. Food and Drug Administration has accepted a supplemental New Drug Application for taletrectinib, a targeted therapy aimed at patients with ROS1‑positive non‑small cell lung cancer. The fi…